WSE:DRF

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Dr.Finance S.A. provides financial products and services for individuals and businesses in Poland. More Details


Snowflake Analysis

Excellent balance sheet with questionable track record.

Share Price & News

How has Dr.Finance's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DRF's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.8%

DRF

-2.9%

PL Capital Markets

-0.1%

PL Market


1 Year Return

232.4%

DRF

96.1%

PL Capital Markets

-17.2%

PL Market

Return vs Industry: DRF exceeded the Polish Capital Markets industry which returned 96.6% over the past year.

Return vs Market: DRF exceeded the Polish Market which returned -17.1% over the past year.


Shareholder returns

DRFIndustryMarket
7 Day-0.8%-2.9%-0.1%
30 Day158.7%6.7%-2.4%
90 Day98.3%-21.9%-10.5%
1 Year232.4%232.4%102.6%96.1%-16.5%-17.2%
3 Year128.8%128.8%36.2%22.0%-27.6%-31.9%
5 Year19.0%19.0%-3.3%-18.8%-15.3%-24.5%

Price Volatility Vs. Market

How volatile is Dr.Finance's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Dr.Finance undervalued compared to its fair value and its price relative to the market?

52.48x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DRF (PLN1.19) is trading above our estimate of fair value (PLN0.71)

Significantly Below Fair Value: DRF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DRF is poor value based on its PE Ratio (52.5x) compared to the PL Capital Markets industry average (12.6x).

PE vs Market: DRF is poor value based on its PE Ratio (52.5x) compared to the Polish market (12.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DRF's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DRF is overvalued based on its PB Ratio (6.4x) compared to the PL Capital Markets industry average (2.1x).


Next Steps

Future Growth

How is Dr.Finance forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.5%

Forecasted Diversified Financials industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dr.Finance has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Dr.Finance performed over the past 5 years?

0.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DRF has high quality earnings.

Growing Profit Margin: DRF's current net profit margins (1.2%) are lower than last year (2.6%).


Past Earnings Growth Analysis

Earnings Trend: DRF has become profitable over the past 5 years, growing earnings by 0.9% per year.

Accelerating Growth: DRF's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DRF had negative earnings growth (-52.7%) over the past year, making it difficult to compare to the Capital Markets industry average (12.7%).


Return on Equity

High ROE: DRF's Return on Equity (12.1%) is considered low.


Next Steps

Financial Health

How is Dr.Finance's financial position?


Financial Position Analysis

Short Term Liabilities: DRF's short term assets (PLN867.0K) exceed its short term liabilities (PLN188.4K).

Long Term Liabilities: DRF's short term assets (PLN867.0K) do not cover its long term liabilities (PLN-100.0).


Debt to Equity History and Analysis

Debt Level: DRF's debt to equity ratio (5.7%) is considered satisfactory.

Reducing Debt: DRF had negative shareholder equity 5 years ago, but is now positive and has therefore improved.

Debt Coverage: DRF's debt is well covered by operating cash flow (161%).

Interest Coverage: DRF's interest payments on its debt are well covered by EBIT (572x coverage).


Balance Sheet


Next Steps

Dividend

What is Dr.Finance current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DRF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DRF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DRF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DRF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DRF's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Pawel Wozniak

no data

Tenure

Mr. Pawel Wozniak serves as President of Management Board of Dr.Finance S.A. (formerly known as Doradcy24 S.A.) Mr. Wozniak has been President of the Management Board at Polcredito Sp. z o.o. since 2010. H ...


Board Members

NamePositionTenureCompensationOwnership
Pawel Szponik
Secretary of the Supervisory Board & Member of the Supervisory Board1.75yrsno datano data
Jerzy Dera
Chairman of Supervisory Boardno datano data0.14%
PLN 6.3k
Lukasz Jagiello
Vice Chairman of Supervisory Board1.75yrsno datano data
Michal Swiatek
Member of the Supervisory Board4.5yrsno datano data
Helena Hanczyn
Member of the Supervisory Boardno datano datano data

1.8yrs

Average Tenure

Experienced Board: DRF's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.


Top Shareholders

Company Information

Dr.Finance S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dr.Finance S.A.
  • Ticker: DRF
  • Exchange: WSE
  • Founded:
  • Industry: Asset Management and Custody Banks
  • Sector: Diversified Financials
  • Market Cap: zł4.450m
  • Shares outstanding: 3.74m
  • Website: https://drfinance.pl

Number of Employees


Location

  • Dr.Finance S.A.
  • ul. Legnicka 17/27
  • Wroclaw
  • 53-671
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DRFWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNJul 2008

Biography

Dr.Finance S.A. provides financial products and services for individuals and businesses in Poland. It offers mortgages, cash and car loans, investment and insurance products, revolving credit, credit for d ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/24 21:47
End of Day Share Price2020/10/23 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.